Stagwell (STGW) Schedules Webcast to Discuss Financial Results for the Three Months Ended March 31, 2024
- 48
PR Newswire
NEW YORK, April 17, 2024
NEW YORK, April 17, 2024 /PRNewswire/ -- Stagwell (NASDAQ: STGW), the challenger network built to transform marketing, will report financial results for the three months ended March 31, 2024, on Wednesday, May 1, 2024, before market open.
Stagwell will host a video webcast to review those results the same day at 8:30 AM (ET). Register here to attend the webcast.
A replay of the webcast will be available following the event at Stagwell's website, https://www.stagwellglobal.com/investors/.
About Stagwell
Stagwell (NASDAQ: STGW) is the network created to transform marketing. We deliver creative performance at scale for the world's most ambitious brands, connecting culture-moving creativity with cutting-edge technology to harmonize the art and science of marketing. Led by entrepreneurs, our more than 13,000 experts in more than 34 countries are united under a single purpose: to generate effectiveness and improve business results for their clients. Join us at www.stagwellglobal.com.
CONTACT:
Ben Allanson
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/stagwell-stgw-schedules-webcast-to-discuss-financial-results-for-the-three-months-ended-march-31-2024-302119569.html
SOURCE Stagwell Inc.
PR Newswire's news distribution, targeting, monitoring and marketing solutions help you connect and engage with target audiences across the globe.
- Wallbridge Participates in NorthX Nickel Private Placement
- ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Globe Life Inc. f/k/a Torchmark Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GL
- PyroGenesis Announces 2024 First Quarter Results
- TerraPay and Al Ansari Exchange Partner to Simplify Money Transfer
- Revolutionizing Crypto Trading: Cwallet Launches Zero-Fee Transactions for IDR and Crypto Trading
- Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing